Wednesday, July 8, 2026

Patent intelligence · US

US 9714232

Substituted piperazine compounds and methods of use thereof

granted A61KA61K31/496A61K31/497A61K31/513
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 11
Applicant portfolio 121
Patent details — US 9714232
Jurisdiction
US
Status
granted
Grant date
Jul 25, 2017
Expiration
Jul 20, 2037
Claims
21
CPC classes
A61K, A61K31/496, A61K31/497, A61K31/513
View on Google Patents ↗

Quick answer

US 9714232 (Substituted piperazine compounds and methods of use thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Jul 25, 2017. Expires Jul 20, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
21
CPC classes
A61K, A61K31/496, A61K31/497, A61K31/513, A61K31/5377, A61K45/06

More from SUNSHINE LAKE PHARMA CO., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12428432

    Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  2. US 12428389

    Diarylamide compound and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  3. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Aug 7, 2045

    granted
  4. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Jun 5, 2045

    granted
  5. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires May 29, 2045

    granted
  6. US 12312348

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires May 22, 2045

    granted
  7. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Apr 3, 2045

    granted
  8. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Mar 20, 2045

    granted

Frequently asked questions

What is US patent 9714232?

US 9714232 (Substituted piperazine compounds and methods of use thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Jul 25, 2017. Expires Jul 20, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9714232?

SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.

When does US 9714232 expire?

Our index shows an expiration date of Jul 20, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.